Protara Therapeutics
TARA
49 hedge funds and large institutions have $212M invested in Protara Therapeutics in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
36% more capital invested
Capital invested by funds: $156M → $212M (+$56.3M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 48 → 49 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10.77% less ownership
Funds ownership: 89.06% → 78.29% (-11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.07M |
| 2 |
BlackRock
New York
|
+$1.93M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.82M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$1.73M |
| 5 |
State Street
Boston,
Massachusetts
|
+$582K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.15M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.84M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.71M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.16M |
| 5 |
CAC
Cowen and Company
New York
|
-$2.09M |
TARA Hedge Fund Activity: Q4 2020 in Review
49 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2020, worth a combined $212M — up 36% from $156M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TARA positions and 5 closed out — a net gain of 1 holder — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.07M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $7.15M sold.
- 49 institutional investors held Protara Therapeutics (TARA) as of Q4 2020, up from 48 in Q3 2020.
- Funds reported $212M of Protara Therapeutics stock for Q4 2020, up 36% quarter-over-quarter.
- 6 funds opened new Protara Therapeutics positions in Q4 2020 and 5 closed out, a net change of +1 holder.
- The largest Protara Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $3.07M added.
- The largest Protara Therapeutics seller in Q4 2020 was Farallon Capital Management, an estimated $7.15M sold.
Based on aggregated 13F filings for Q4 2020.